Clinical Trials Logo

Clinical Trial Summary

COVID-19 is arguably the biggest challenge critical care medicine has been confronted with since its conception. Critical care services around the world are flooded by patients presenting with severe respiratory failure who require prolonged treatment in the ICU. Despite the support provided, outcomes are poor, particularly in ventilated patients. Many unanswered questions remain regarding the pathophysiology of COVID-19, particularly in severely ill patients. No evidence-based treatment is currently available, yet different often experimental therapies are administered to patients. As experience grows, new phenotypes are recognized, and unreported complications are observed in the most severely ill patients. Although many registries are currently including patients, few of them focus on ICU patients and their specific treatments and newly observed complications and challenges. Although the pandemic may appear on its return in many countries that are now easing the restrictions that were put in place to limit the spread of the disease, it can be expected that COVID-19 will be a continued challenge in ICUs globally until a safe and effective vaccine is found. Efforts to study the disease should continue in order to advance our understanding of the disease as well as improve treatment options.


Clinical Trial Description

This is a multicenter, international, anonymized point prevalence study. Patients who were present in the ICU on the day in April 2020 with the highest number of COVID-19 patients in the unit. Data can be entered in the database until July 2020. Retrospective data collection and entry is allowed. Subjects believed to fulfill all eligibility criteria, and none of the exclusion criteria, detailed in the relevant section of this protocol, will be included in the study. Data will be entered in the database anonymously. Data will consist of two core elements: 1. Center data (to be completed once) 2. Patient data For different domains with specific, highly relevant and un(der)explored ICU research questions, an focused data set is to be completed. These domains include: 1. Respiratory 2. Coagulation and thrombo-embolic events 3. Infectious complications 4. Rehabilitation 5. Renal ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04836065
Study type Observational
Source University Hospital, Ghent
Contact
Status Completed
Phase
Start date July 1, 2020
Completion date December 31, 2020

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04997551 - Double Blind Randomized Clinical Trial of Use of Colchicine Added to Standard Treatment in Hospitalized With Covid-19 Phase 3
Recruiting NCT04977024 - SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer Phase 2
Completed NCT05049226 - Third Dose Vaccination With AstraZeneca or Pfizer COVID-19 Vaccine Among Adults Received Sinovac COVID-19 Vaccine Phase 2
Terminated NCT04455815 - A Trial Looking at the Use of Camostat in People Who Have Tested Positive for Coronavirus (COVID-19) (SPIKE-1) Phase 2
Completed NCT04666025 - SARS-CoV-2 Donor-Recipient Immunity Transfer
Completed NCT04662437 - The Status of Parathyroid Hormone Secretion in Covid-19 Patients
Recruiting NCT05792878 - Study of COVID-19 Infection and Its Clinical Prognosis in Chronic Hepatitis B Patients With Antiviral Therapy
Completed NCT04659200 - Thyroid Function Tests and Status of Thyroid Autoantibodies in Covid-19 Patients
Recruiting NCT04470583 - Evaluating Clinical Parameters of COVID-19 in Pregnancy
Withdrawn NCT04377568 - Efficacy of Human Coronavirus-immune Convalescent Plasma for the Treatment of COVID-19 Disease in Hospitalized Children Phase 2
Completed NCT04848610 - The Factors That Affect the Infection of COVID-19
Recruiting NCT04582903 - Send-In Sample Collection for Comprehensive Analyses of Innate and Adaptive Immune Responses During Acute COVID-19 and Convalescence
Recruiting NCT06032000 - Evaluation of Safety and Immunogenicity of a SARS-CoV-2(Severe Acute Respiratory Syndrome Coronavirus 2) Booster Vaccine (LEM-mR203) Phase 1
Terminated NCT04941703 - "CHANGE COVID-19 Severity" Phase 1/Phase 2
Active, not recruiting NCT04639466 - A Synthetic MVA-based SARS-CoV-2 Vaccine, GEO-CM04S1, for the Prevention of COVID-19 Infection Phase 1/Phase 2
Completed NCT04575038 - CRISIS2: A Phase 2 Study of the Safety and Antiviral Activity of Brequinar in Non-hospitalized Pts With COVID-19 Phase 2
Recruiting NCT05022446 - The Impact of COVID-19 on Pulmonary Procedures
Completed NCT04347798 - IMPACT: IMPact of Antimalarials on Covid-19 Infections in RAPPORT
Active, not recruiting NCT04650178 - Well-being in Cancer Patients With Neuropathy During COVID-19 Who Participated in Prior Clinical Trials
Recruiting NCT04169542 - Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cancer Undergoing Breast Surgery